Business ❯Pharmaceuticals

Vaccine Development

Moderna Novavax Market Impact AstraZeneca Market Reactions Corporate Governance Cancer Vaccine Pfizer Moderna Inc. Clinical Trials Corporate Deals Contracts Corporate Communication Collaboration Agreements Market Response Pricing Strategies COVID-19 Vaccine Market Competition mRNA Technology Investment Decisions Covid-19 Vaccines Research and Development Seattle-based

Moderna’s mRNA-1010 Flu Vaccine Outperforms Standard Shot and Advances Toward Approval

Regulators will review Moderna’s standalone flu vaccine application later this year based on Phase 3 results showing superior efficacy

GSK and Bharat Biotech to Cut Malaria Vaccine Price Below $5 by 2028

FDA Expands Moderna RSV Vaccine to Adults 18–59 at Risk

FDA Approves Moderna’s mNEXSPIKE for Seniors and High-Risk Adults as CDC Drops Recommendations for Healthy Children and Pregnant Women

HHS Withdraws $766 Million From Moderna’s Bird Flu Vaccine Program

Moderna Withdraws Flu-COVID Vaccine Application After FDA Requests More Data

FDA Grants Limited Approval to Novavax’s COVID-19 Vaccine

EU Tribunal Rules Commission Wrongfully Withheld Vaccine SMS

EU Court Orders Disclosure of Von der Leyen's Pfizer Texts

Vaxart's Oral Norovirus Vaccine Shows Promise in Early Trials for Elderly Adults

Moderna Wins Patent Case Against BioNTech and Pfizer Over mRNA Technology

Scientists Identify New Coronavirus in Bats Capable of Infecting Humans

AstraZeneca Cancels £450m UK Vaccine Plant Investment

BioNTech Settles COVID-19 Vaccine Royalty Disputes for $1.2 Billion

FDA Authorizes New Novavax Vaccine Targeting Omicron Variant

AstraZeneca's £450m UK Vaccine Plant Faces Funding Uncertainty

Pfizer Seeks FDA Approval for RSV Vaccine in Young Adults